Intrinsic value of Staar Surgical - STAA

Previous Close

$41.34

  Intrinsic Value

$0.24

stock screener

  Rating & Target

str. sell

-99%

Previous close

$41.34

 
Intrinsic value

$0.24

 
Up/down potential

-99%

 
Rating

str. sell

We calculate the intrinsic value of STAA stock by summing up the current values of future distributable cash flows generated by the company and dividing the sum by the number of outstanding shares. As such, the intrinsic value calculation depends entirely on projections. The more accurate your projections of the company's performance are - the more reliable is the intrinsic value calculation result. Please make sure to check the stock valuation input data below and adjust it if necessary. The quality of the output (intrinsic valuation result) is only as good as the quality of the input. See also DISCLAIMERS.

STOCK VALUATION INPUT DATA

Revenue (in 0001), $M
Initial revenue growth rate, %
Terminal revenue growth rate, %
Revenue decline factor
Initial discount rate, %
Discount rate multiplier
Variable cost ratio, %
Fixed operating expenses, $M
Interest rate on debt, %
Effective corporate tax rate, %
Production assets / Revenue, %
Life of production assets, yrs
Working capital / Revenue, %
Revenue / Adjusted assets
Adjusted equity ratio
Cash flow adjustment, % of Revenue
Book value of equity, $M
Shares outstanding, mln
Market capitalization, $bln 1.7

 

FINANCIAL STATEMENTS FORECAST and PRESENT VALUE CALCULATION

Fiscal year
   2
   3
   4
   5
   6
   7
   8
   9
   10
   11
   12
   13
   14
   15
   16
   17
   18
   19
   20
   21
   22
   23
   24
   25
   26
   27
   28
   29
   30
   31

INCOME STATEMENT

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revenue growth rate, %
  54.60
  49.64
  45.18
  41.16
  37.54
  34.29
  31.36
  28.72
  26.35
  24.22
  22.29
  20.57
  19.01
  17.61
  16.35
  15.21
  14.19
  13.27
  12.44
  11.70
  11.03
  10.43
  9.88
  9.40
  8.96
  8.56
  8.20
  7.88
  7.60
  7.34
Revenue, $m
  140
  210
  304
  430
  591
  793
  1,042
  1,342
  1,695
  2,106
  2,575
  3,105
  3,695
  4,345
  5,056
  5,825
  6,651
  7,534
  8,472
  9,463
  10,507
  11,602
  12,749
  13,947
  15,196
  16,497
  17,851
  19,258
  20,721
  22,241
Variable operating expenses, $m
  162
  242
  351
  495
  681
  914
  1,201
  1,545
  1,953
  2,425
  2,966
  3,576
  4,255
  5,005
  5,823
  6,709
  7,661
  8,677
  9,757
  10,899
  12,101
  13,363
  14,684
  16,063
  17,502
  19,000
  20,559
  22,180
  23,865
  25,616
Fixed operating expenses, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total operating expenses, $m
  162
  242
  351
  495
  681
  914
  1,201
  1,545
  1,953
  2,425
  2,966
  3,576
  4,255
  5,005
  5,823
  6,709
  7,661
  8,677
  9,757
  10,899
  12,101
  13,363
  14,684
  16,063
  17,502
  19,000
  20,559
  22,180
  23,865
  25,616
Operating income, $m
  -21
  -32
  -46
  -65
  -90
  -121
  -158
  -204
  -257
  -320
  -391
  -471
  -561
  -659
  -767
  -884
  -1,009
  -1,143
  -1,285
  -1,436
  -1,594
  -1,760
  -1,934
  -2,116
  -2,306
  -2,503
  -2,709
  -2,922
  -3,144
  -3,375
EBITDA, $m
  -18
  -26
  -38
  -54
  -74
  -100
  -131
  -169
  -213
  -265
  -324
  -390
  -465
  -546
  -636
  -732
  -836
  -947
  -1,065
  -1,190
  -1,321
  -1,459
  -1,603
  -1,754
  -1,911
  -2,074
  -2,244
  -2,421
  -2,605
  -2,796
Interest expense (income), $m
  0
  0
  1
  2
  3
  5
  8
  11
  14
  19
  24
  30
  37
  45
  54
  63
  74
  85
  97
  110
  124
  139
  154
  170
  187
  205
  224
  243
  263
  284
  305
Earnings before tax, $m
  -22
  -33
  -48
  -69
  -95
  -128
  -169
  -218
  -276
  -344
  -421
  -508
  -605
  -713
  -830
  -958
  -1,094
  -1,240
  -1,396
  -1,560
  -1,733
  -1,915
  -2,105
  -2,304
  -2,511
  -2,727
  -2,951
  -3,185
  -3,428
  -3,680
Tax expense, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Net income, $m
  -22
  -33
  -48
  -69
  -95
  -128
  -169
  -218
  -276
  -344
  -421
  -508
  -605
  -713
  -830
  -958
  -1,094
  -1,240
  -1,396
  -1,560
  -1,733
  -1,915
  -2,105
  -2,304
  -2,511
  -2,727
  -2,951
  -3,185
  -3,428
  -3,680

BALANCE SHEET

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cash and short-term investments, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total assets, $m
  104
  156
  227
  320
  441
  592
  777
  1,000
  1,264
  1,570
  1,920
  2,315
  2,755
  3,240
  3,770
  4,344
  4,960
  5,618
  6,318
  7,057
  7,835
  8,652
  9,507
  10,401
  11,332
  12,302
  13,312
  14,361
  15,452
  16,586
Adjusted assets (=assets-cash), $m
  104
  156
  227
  320
  441
  592
  777
  1,000
  1,264
  1,570
  1,920
  2,315
  2,755
  3,240
  3,770
  4,344
  4,960
  5,618
  6,318
  7,057
  7,835
  8,652
  9,507
  10,401
  11,332
  12,302
  13,312
  14,361
  15,452
  16,586
Revenue / Adjusted assets
  1.346
  1.346
  1.339
  1.344
  1.340
  1.340
  1.341
  1.342
  1.341
  1.341
  1.341
  1.341
  1.341
  1.341
  1.341
  1.341
  1.341
  1.341
  1.341
  1.341
  1.341
  1.341
  1.341
  1.341
  1.341
  1.341
  1.341
  1.341
  1.341
  1.341
Average production assets, $m
  18
  27
  40
  56
  77
  103
  135
  174
  220
  274
  335
  404
  480
  565
  657
  757
  865
  979
  1,101
  1,230
  1,366
  1,508
  1,657
  1,813
  1,976
  2,145
  2,321
  2,504
  2,694
  2,891
Working capital, $m
  34
  51
  74
  104
  143
  192
  252
  325
  410
  510
  623
  751
  894
  1,052
  1,223
  1,410
  1,610
  1,823
  2,050
  2,290
  2,543
  2,808
  3,085
  3,375
  3,678
  3,992
  4,320
  4,661
  5,015
  5,382
Total debt, $m
  20
  39
  65
  99
  143
  198
  267
  348
  445
  558
  686
  831
  993
  1,171
  1,365
  1,575
  1,802
  2,043
  2,300
  2,571
  2,857
  3,157
  3,470
  3,798
  4,140
  4,496
  4,867
  5,252
  5,652
  6,068
Total liabilities, $m
  38
  57
  83
  118
  162
  217
  285
  367
  464
  576
  705
  850
  1,011
  1,189
  1,384
  1,594
  1,820
  2,062
  2,319
  2,590
  2,875
  3,175
  3,489
  3,817
  4,159
  4,515
  4,885
  5,271
  5,671
  6,087
Total equity, $m
  66
  99
  144
  203
  279
  375
  492
  633
  800
  994
  1,216
  1,466
  1,744
  2,051
  2,387
  2,750
  3,140
  3,556
  3,999
  4,467
  4,960
  5,477
  6,018
  6,584
  7,173
  7,787
  8,426
  9,091
  9,781
  10,499
Total liabilities and equity, $m
  104
  156
  227
  321
  441
  592
  777
  1,000
  1,264
  1,570
  1,921
  2,316
  2,755
  3,240
  3,771
  4,344
  4,960
  5,618
  6,318
  7,057
  7,835
  8,652
  9,507
  10,401
  11,332
  12,302
  13,311
  14,362
  15,452
  16,586
Debt-to-equity ratio
  0.300
  0.390
  0.450
  0.490
  0.510
  0.530
  0.540
  0.550
  0.560
  0.560
  0.560
  0.570
  0.570
  0.570
  0.570
  0.570
  0.570
  0.570
  0.580
  0.580
  0.580
  0.580
  0.580
  0.580
  0.580
  0.580
  0.580
  0.580
  0.580
  0.580
Adjusted equity ratio
  0.633
  0.633
  0.633
  0.633
  0.633
  0.633
  0.633
  0.633
  0.633
  0.633
  0.633
  0.633
  0.633
  0.633
  0.633
  0.633
  0.633
  0.633
  0.633
  0.633
  0.633
  0.633
  0.633
  0.633
  0.633
  0.633
  0.633
  0.633
  0.633
  0.633

CASH FLOW

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net income, $m
  -22
  -33
  -48
  -69
  -95
  -128
  -169
  -218
  -276
  -344
  -421
  -508
  -605
  -713
  -830
  -958
  -1,094
  -1,240
  -1,396
  -1,560
  -1,733
  -1,915
  -2,105
  -2,304
  -2,511
  -2,727
  -2,951
  -3,185
  -3,428
  -3,680
Depreciation, amort., depletion, $m
  4
  6
  8
  11
  16
  21
  27
  35
  44
  55
  67
  81
  96
  113
  131
  151
  173
  196
  220
  246
  273
  302
  331
  363
  395
  429
  464
  501
  539
  578
Funds from operations, $m
  -18
  -27
  -40
  -57
  -80
  -107
  -142
  -183
  -232
  -289
  -354
  -427
  -509
  -600
  -699
  -806
  -921
  -1,045
  -1,176
  -1,314
  -1,460
  -1,613
  -1,773
  -1,941
  -2,116
  -2,298
  -2,487
  -2,684
  -2,889
  -3,102
Change in working capital, $m
  12
  17
  23
  30
  39
  49
  60
  72
  86
  99
  114
  128
  143
  157
  172
  186
  200
  214
  227
  240
  253
  265
  278
  290
  302
  315
  328
  341
  354
  368
Cash from operations, $m
  -30
  -44
  -63
  -88
  -119
  -157
  -202
  -256
  -318
  -388
  -467
  -556
  -652
  -757
  -871
  -992
  -1,121
  -1,258
  -1,402
  -1,554
  -1,712
  -1,878
  -2,051
  -2,231
  -2,418
  -2,613
  -2,815
  -3,025
  -3,243
  -3,469
Maintenance CAPEX, $m
  -2
  -4
  -5
  -8
  -11
  -15
  -21
  -27
  -35
  -44
  -55
  -67
  -81
  -96
  -113
  -131
  -151
  -173
  -196
  -220
  -246
  -273
  -302
  -331
  -363
  -395
  -429
  -464
  -501
  -539
New CAPEX, $m
  -6
  -9
  -12
  -16
  -21
  -26
  -32
  -39
  -46
  -53
  -61
  -69
  -77
  -85
  -92
  -100
  -107
  -115
  -122
  -129
  -136
  -142
  -149
  -156
  -162
  -169
  -176
  -183
  -190
  -198
Cash from investing activities, $m
  -8
  -13
  -17
  -24
  -32
  -41
  -53
  -66
  -81
  -97
  -116
  -136
  -158
  -181
  -205
  -231
  -258
  -288
  -318
  -349
  -382
  -415
  -451
  -487
  -525
  -564
  -605
  -647
  -691
  -737
Free cash flow, $m
  -39
  -57
  -81
  -112
  -151
  -198
  -255
  -322
  -398
  -486
  -583
  -691
  -810
  -938
  -1,076
  -1,224
  -1,380
  -1,546
  -1,720
  -1,903
  -2,094
  -2,294
  -2,502
  -2,718
  -2,943
  -3,177
  -3,420
  -3,672
  -3,934
  -4,206
Issuance/(repayment) of debt, $m
  13
  19
  26
  34
  44
  55
  68
  82
  97
  112
  128
  145
  162
  178
  194
  210
  226
  242
  257
  271
  286
  300
  314
  328
  342
  356
  370
  385
  400
  416
Issuance/(repurchase) of shares, $m
  45
  66
  93
  128
  171
  224
  287
  359
  443
  538
  642
  758
  884
  1,020
  1,166
  1,321
  1,484
  1,657
  1,838
  2,028
  2,226
  2,432
  2,646
  2,869
  3,101
  3,341
  3,590
  3,849
  4,118
  4,397
Cash from financing (excl. dividends), $m  
  58
  85
  119
  162
  215
  279
  355
  441
  540
  650
  770
  903
  1,046
  1,198
  1,360
  1,531
  1,710
  1,899
  2,095
  2,299
  2,512
  2,732
  2,960
  3,197
  3,443
  3,697
  3,960
  4,234
  4,518
  4,813
Total cash flow (excl. dividends), $m
  20
  28
  38
  50
  65
  81
  100
  120
  142
  164
  188
  212
  236
  260
  284
  307
  330
  353
  375
  396
  417
  438
  458
  479
  499
  520
  541
  563
  585
  608
Retained Cash Flow (-), $m
  -45
  -66
  -93
  -128
  -171
  -224
  -287
  -359
  -443
  -538
  -642
  -758
  -884
  -1,020
  -1,166
  -1,321
  -1,484
  -1,657
  -1,838
  -2,028
  -2,226
  -2,432
  -2,646
  -2,869
  -3,101
  -3,341
  -3,590
  -3,849
  -4,118
  -4,397
Prev. year cash balance distribution, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash flow adjustment, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash available for distribution, $m
  -25
  -38
  -55
  -78
  -107
  -143
  -187
  -240
  -302
  -373
  -455
  -546
  -648
  -760
  -882
  -1,013
  -1,154
  -1,304
  -1,464
  -1,632
  -1,809
  -1,994
  -2,188
  -2,390
  -2,601
  -2,821
  -3,049
  -3,287
  -3,533
  -3,790
Discount rate, %
  4.30
  4.52
  4.74
  4.98
  5.23
  5.49
  5.76
  6.05
  6.35
  6.67
  7.00
  7.35
  7.72
  8.11
  8.51
  8.94
  9.39
  9.86
  10.35
  10.87
  11.41
  11.98
  12.58
  13.21
  13.87
  14.56
  15.29
  16.05
  16.86
  17.70
PV of cash for distribution, $m
  -24
  -35
  -48
  -64
  -83
  -104
  -126
  -150
  -173
  -196
  -216
  -233
  -246
  -255
  -259
  -257
  -251
  -240
  -225
  -207
  -187
  -165
  -143
  -122
  -101
  -82
  -65
  -51
  -39
  -29
Current shareholders' claim on cash, %
  90.5
  82.3
  75.2
  69.1
  63.7
  59.0
  54.8
  51.0
  47.7
  44.7
  42.0
  39.5
  37.3
  35.2
  33.3
  31.6
  30.0
  28.5
  27.1
  25.7
  24.5
  23.4
  22.3
  21.3
  20.3
  19.4
  18.6
  17.8
  17.0
  16.3

STAAR Surgical Company designs, develops, manufactures and sells implantable lenses for the eye and delivery systems used to deliver the lenses into the eye. It operates in the ophthalmic surgical market segment. Its principal products are intraocular lenses used in cataract surgery and implantable collamer lenses used in refractive surgery. It makes lenses used across the world in corrective or refractive surgery, and makes lenses for use in surgery that treats cataracts. Its refractive surgery corrects the types of visual disorders that glasses or contact lenses have treated (myopia, hyperopia, astigmatism and presbyopia). Its refractive surgery corrects the types of visual disorders that glasses or contact lenses have treated (myopia, hyperopia, astigmatism and presbyopia). As of December 30, 2016, it sold its products in more than 60 countries, with direct distribution in the United States, Canada, Japan and Spain, and independent distribution in the remainder of the world.

FINANCIAL RATIOS  of  Staar Surgical (STAA)

Valuation Ratios
P/E Ratio -140.3
Price to Sales 20.5
Price to Book 44.3
Price to Tangible Book
Price to Cash Flow 1683.8
Price to Free Cash Flow -841.9
Growth Rates
Sales Growth Rate 6.5%
Sales - 3 Yr. Growth Rate %
EPS Growth Rate %
EPS - 3 Yr. Growth Rate %
Capital Spending Gr. Rate 50%
Cap. Spend. - 3 Yr. Gr. Rate 0%
Financial Strength
Quick Ratio 3
Current Ratio 0
LT Debt to Equity 5.3%
Total Debt to Equity 18.4%
Interest Coverage 0
Management Effectiveness
Return On Assets -18.8%
Ret/ On Assets - 3 Yr. Avg. -14.5%
Return On Total Capital -27%
Ret/ On T. Cap. - 3 Yr. Avg. -20.6%
Return On Equity -31.2%
Return On Equity - 3 Yr. Avg. -23.5%
Asset Turnover 1.3
Profitability Ratios
Gross Margin 70.7%
Gross Margin - 3 Yr. Avg. 68.3%
EBITDA Margin -11%
EBITDA Margin - 3 Yr. Avg. -8.5%
Operating Margin -15.9%
Oper. Margin - 3 Yr. Avg. -11%
Pre-Tax Margin -14.6%
Pre-Tax Margin - 3 Yr. Avg. -11.5%
Net Profit Margin -14.6%
Net Profit Margin - 3 Yr. Avg. -11.5%
Effective Tax Rate 0%
Eff/ Tax Rate - 3 Yr. Avg. -1.9%
Payout Ratio 0%

STAA stock valuation input parameters

Revenue. Company's revenue (or sales) is always the starting point of any cash flow forecast. In the STAA stock intrinsic value calculation we used $90.611 million for the last fiscal year's total revenue generated by Staar Surgical. The default revenue input number comes from 0001 income statement of Staar Surgical. You may change it if you feel that it should be adjusted for some unusual circumstances that are not expected to be repeated in the future or if you already know (from interim financial statements, for example) that this year's revenue is going to be quite different.

Revenue growth rate. Forecasted future revenue growth rate is the most important input parameter for the intrinsic value calculation. Unlike other input parameters that are reasonably expected to be in line with their historic averages or their historic trends, the revenue growth rate by and large is a wild card: nobody really knows what the company's revenue will be in the future. Of course, the level of unpredictability is different for different industries (utility companies being the most predictable and, thus, less risky).
    We use three input parameters to forecast the revenue growth rate in our STAA stock valuation model: a) initial revenue growth rate of 54.6% whose default value is the revenue growth rate in the most recent quarter compared to the quarterly revenue a year ago; b) terminal revenue growth rate of 5% whose default value is chosen to be close to the average nominal (i.e. not adjusted for inflation) GDP growth rate; and c) revenue decline factor of 0.9, which stipulates that revenue growth rate in each forecasted year will be equal to the difference of the revenue growth rate in the preceding year and the terminal revenue growth rate multiplied by this revenue decline factor (with the passage of time the revenue growth rate will be approaching the terminal revenue growth rate, but not quite reaching it - though the difference could be infinitesimally small).
    At the revenue decline factor of 1, the future revenue growth rate is forecasted to be constant and equal to the initial revenue growth rate. The smaller the revenue decline factor, the faster the revenue growth rate will approach the terminal revenue growth.

Discount rate. The discount rate is used for determining the present value of future cash flows: future cash flows are "discounted" as at normal conditions (that translate into positive expected return on investment) one dollar today is worth more than the same dollar in the future. Unlike all other valuation models, we use variable discount rate, i.e. it increases for each consecutive year. This is done to account for higher risk of cash flows coming in further in the future.
    The initial discount rate of 4.3%, whose default value for STAA is calculated based on our internal credit rating of Staar Surgical, is applied to the cash flow expected to be received a year from now (well, actually, to be precise, in the financial year following the base year - the last year for which we have financial statements). For each consecutive year the discount rate is multiplied by the discount rate multiplier of 1.05, e.i. each year it increases by 5%. Feel free to change this number to correspond to your level of risk assessment of Staar Surgical.
    By the way, it is easy to set the discount rate to be constant (this would make comparison with other valuation models easier): just set the discount rate multiplier equal to 1 and chose the magnitude of the initial discount rate to your liking.

Variable cost ratio is the ratio of variable costs (i.e. costs that fluctuate with fluctuation of the volume of production) to the revenue expressed as a percentage. In the calculation of intrinsic value of STAA stock the variable cost ratio is equal to 115.4%.

Fixed operating expenses is just that - expenses that are not dependant on the volume of production. They are set to $0 million in the base year in the intrinsic value calculation for STAA stock. These expenses increase with the level of inflation in subsequent years.

Interest rate on debt is the average all-in rate of interest paid by the company on its debt. It is set at 5.4% for Staar Surgical.

Corporate tax rate of 27% is the nominal tax rate for Staar Surgical. In reality, companies find ways to pay much less taxes than that or not to pay them at all.

Cash flow adjustment could be used for any adjustment the investor deems necessary. Most commonly we use this field to account for stock options-related effects in excess of what is reported on the company's income statement. The cash flow adjustment is expressed as a percentage of the revenue, and in the current valuation of the STAA stock is equal to 0%.

Production assets are the company's assets used for manufacturing products or provision of services. In the valuation model input table they are expressed as a percentage of revenue and for STAA are equal to 13%.

Life of production assets of 3.9 years is the average useful life of capital assets used in Staar Surgical operations. It is used to calculate yearly capital expenditures needed to keep these assets in good order - we call it the maintenance CAPEX.

Working capital is the difference between the company's current assets and liabilities. In the model we use the ratio of working capital to revenue, which for STAA is equal to 24.2%. A negative number means that the company is apt at using financial resources of its suppliers and customers; a large positive number, on the other hand, means that it either provides in-kind financing to others or is not good at managing its inventories.

Book value of equity - $42.936 million for Staar Surgical - is used in calculation of the "floor" for intrinsic valuation based on the discounted cash flow (DCF) method. Even if the prospects are very bad for a company, its assets could always be sold now for their current fair market value.

Shares outstanding of 41.903 million for Staar Surgical is needed to calculate the intrinsic value of one share.

Market capitalization is used here only for reference purposes and as a quick check that the share price and the number of shares outstanding numbers are correct - something especially to be cognizant about at stock splits. So, the market capitalization of Staar Surgical at the current share price and the inputted number of shares is $1.7 billion.

RELATED COMPANIES Price Int.Val. Rating
GKOS Glaukos 59.47 3.86  str.sell
COO Cooper 257.21 429.58  str.buy
EYES Second Sight M 1.28 0.03  str.sell
ATRI Atrion 725.12 380.16  sell
IRIX Iridex 4.91 0.64  str.sell

COMPANY NEWS

▶ Position Size Reduces Risk And Increases Opportunities   [Nov-16-18 01:12PM  Investor's Business Daily]
▶ Staar Surgical: 3Q Earnings Snapshot   [04:26PM  Associated Press]
▶ Los Angeles stocks that are driving Wall Street's latest bull run   [Aug-23-18 02:31PM  American City Business Journals]
▶ STAAR Surgical Announces Closing of Common Stock Offering   [Aug-10-18 09:45AM  Business Wire]
▶ STAAR Surgical Announces Public Offering of Common Stock   [Aug-07-18 04:01PM  Business Wire]
▶ Why STAAR Surgical Company Stock Soared Today   [Aug-02-18 01:00PM  Motley Fool]
▶ Staar Surgical: 2Q Earnings Snapshot   [05:32PM  Associated Press]
▶ STAAR Surgical Announces Resolution of FDA Warning Letter   [Jun-20-18 06:00AM  Business Wire]
▶ Staar Surgical: 1Q Earnings Snapshot   [May-02-18 05:31PM  Associated Press]
▶ Staar Surgical posts 4Q loss   [Feb-28-18 05:17PM  Associated Press]
▶ Staar Surgical posts 3Q profit   [Nov-08-17 04:43PM  Associated Press]
▶ STAAR Surgical Names Deborah Andrews as CFO   [Sep-28-17 10:20AM  PR Newswire]
▶ Analysts Take Action on Health Care Stocks   [Sep-26-17 01:43PM  GuruFocus.com]
▶ Staar Surgical reports 2Q loss   [Aug-03-17 12:23AM  Associated Press]
▶ STAAR Surgical Reports Second Quarter 2017 Results   [Aug-02-17 04:01PM  PR Newswire]
▶ ETFs with exposure to STAAR Surgical Co. : May 8, 2017   [May-08-17 05:16PM  Capital Cube]
▶ Staar Surgical reports 1Q loss   [May-03-17 05:06PM  Associated Press]
▶ STAAR Surgical Names Deborah Andrews Interim CFO   [Apr-05-17 07:00AM  PR Newswire]

CONTACT US       ASSET ALLOCATION

About X-FIN       Site news       Privacy policy       Terms of use       FAQ

Copyright © X-FIN.com 2005-2018. All rigths reserved.